Level Four Advisory Services’s Harmony Biosciences HRMY Stock Holding History

Level Four Advisory Services’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,615	Closed	-$309K	–	788
2022 Q4	$309K	Sell	5,615 -8,480	-60%	-$466K	0.02%	512
2022 Q3	$624K	Buy	+14,095	New	+$688K	0.06%	277

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Level Four Advisory Services's HRMY Position: Q1 2023 in Review

Level Four Advisory Services sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 5,615 shares — an estimated $309K sold.

Level Four Advisory Services first reported a position in HRMY in Q3 2022 and held it in 2 quarters. The position peaked at $624K in Q3 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

Level Four Advisory Services reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
Level Four Advisory Services sold 5,615 Harmony Biosciences shares in Q1 2023, an estimated $309K.
Level Four Advisory Services first reported a position in Harmony Biosciences in Q3 2022 and held it in 2 quarters.
Level Four Advisory Services's Harmony Biosciences position peaked at $624K in Q3 2022.
217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Level Four Advisory Services's 13F filing for Q1 2023, filed 5 Jun 2023.